Viking Therapeutics Inc (VKTX)

[Biorat]

(Take a look at CNTX) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it given the upcoming Society for Immunotherapy of Cancer meeting will alert investors to the potential. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the market value of a pending CLND6 blockbuster. There are other irons in the fire at Context Therapeutics for share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX stock had been beaten down just like the shares of Viking Therapeutics(VKTX) Had been before running up to over $25 a share.

Right now the shares of CNTX are held tight and only have a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock stock as a buy. There is a growing consensus that forecast is far to conservative. $6-$15 seems a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this.... Don't believe it? Look over VKTX where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months